相关实验视频
Updated: Jun 6, 2025
07:27
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
24.6K
儿科慢性心力衰竭:医学治疗的特定年龄考虑
1Children's Heart Centre, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic. karel.koubsky@fnmotol.cz.
Physiological research
|November 26, 2024
概括
儿童慢性心力衰竭 (CHF) 治疗不同于成年人由于独特的病理生理学. 本综述讨论了优化儿科心脏不全症的医疗疗,重点关注独特的分子和细胞机制.
科学领域:
- 心脏病学 心脏病学
- 儿科医学 儿科医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性心力衰竭 (CHF) 在儿童中很少见,但死亡率很高.
- 儿科心血管疾病治疗通常依赖于成人指导方针,对儿科疗效的证据有限.
- 儿科CHF的病理生理学可能在分子和细胞层面上与成年人不同,这会影响治疗方法.
研究的目的:
- 审查医疗治疗儿童慢性心血管功能障碍与全身左心室功能障碍的主要病理生理目标.
- 讨论当前和新兴的儿科心血管功能障碍的药物治疗方法.
- 突出需要儿科专用证据和治疗策略的需要.
主要方法:
- 关于儿科心血管疾病病理生理学和治疗现有文献的综述.
- 基于其作用机制和儿童群体的证据对药理学药物的讨论.
- 分析成人和儿科心脏不全症之间的差异.
主要成果:
- 儿科CHF的病理生理学涉及不同的分子路径,可能导致纤维化和缩不如成人.
- 关键的治疗目标包括优化预负载/后负载,减少心肌细胞亡/亡和纤维化,以及控制心肌氧消耗.
- 基石疗法包括ACE抑制剂 (ACEI),β抑制剂和矿物质皮质类受体对抗剂,组织ACEI和β1选择性β抑制剂的潜在益处.
结论:
- 儿科心血管疾病需要量身定制的治疗策略,考虑到其独特的病理生理学.
- 优化心肌条件对于利用儿科心肌的再生潜力至关重要.
- 需要进一步的研究,以建立基于证据的指导方针,用于儿科CHF药疗,包括新型药物,如血管激素受体-neprilysin抑制剂和SGLT2抑制剂.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:28Mitral Regurgitation IV: Nursing Management
3
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
3
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2